A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.

Smith, Patrick F; Krishnarajah, Janakan; Nunn, Philip A; Hill, Ron J; Karr, Dane; Tam, D; Masjedizadeh, Mohammad; Funk, Jens O; Gourlay, Steve G

Smith, Patrick F; Krishnarajah, Janakan; Nunn, Philip A; Hill, Ron J; Karr, Dane; Tam, D; Masjedizadeh, Mohammad; Funk, Jens O; Gourlay, Steve G.

Affiliation

Smith PF; d3 Medicine, A Certara Company, Parsippany, New Jersey, USA.
Krishnarajah J; Linear Clinical Research, Perth, Australia.
Nunn PA; Principia Biopharma, Melbourne, Australia.
Hill RJ; Principia Biopharma, Melbourne, Australia.
Karr D; Principia Biopharma, Melbourne, Australia.
Tam D; Principia Biopharma, Melbourne, Australia.
Masjedizadeh M; Principia Biopharma, Melbourne, Australia.
Funk JO; Principia Biopharma, Melbourne, Australia.
Gourlay SG; Principia Biopharma, Melbourne, Australia.

Br J Clin Pharmacol ; 83(11): 2367-2376, 2017 Nov.

Article de En | MEDLINE | ID: mdl-28636208

Sujet(s)
Mots clés

Bruton's tyrosine kinase; PRN1008; autoimmune diseases

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protein-tyrosine kinases / Agranulocytes / Inhibiteurs de protéines kinases Type d'étude: Clinical_trials Limites: Adult / Humans / Male Langue: En Journal: Br J Clin Pharmacol Année: 2017 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google